| ROSWELL PARK CANCER INSTITUTE | |||
| Site name: | Roswell Park Cancer Institute | Active Prostate Cancer Clinical Trials: | |
| Contact: | Donald L. Trump, MD | That match your search: | No search performed |
| Phone: | 1-877-ASK-RPCI (1-877-275-7724) | ||
| Site email: | donald.trump@roswellpark.org | ||
Prostate care at RPCI integrates surgical, radiation, and medical oncology specialists tailoring personalized treatment plans. They work in concert with your primary care physician, ensuring continuity of care from diagnosis through long-term follow-up.
Strong connections between research and clinical care is evident in medical advances and technologies developed at RPCI:
- Robot-assisted surgery and other minimally invasive techniques are now used to perform 99% of prostate cancer surgeries at Roswell Park.
- Prostate Specific Antigen (PSA) test detects prostate cancer 5–10 years earlier than previous screening methods.
- LNCaP, the most studied prostate cancer cell line in the world.
- Photodynamic therapy (PDT) uses lasers to activate photosensitive drugs to kill cancer cells.
RPCI is a member of the National Comprehensive Cancer Network (NCCN), an alliance of the nation’s top cancer centers, which develops the most widely used guidelines for cancer early detection and treatment. RPCI physicians who are members of the NCCN Prostate Cancer Guidelines Committee are:
- James Mohler, MD, Chair of Urology and Chair of the Prostate Cancer Treatment Guideline Committee.
- Michael Kuettel, MD, PhD, MBA, Chair of Radiation Medicine and co-author of the original Prostate Cancer Treatment Guideline (1999).
- Robert Huben, MD, the Robert P. Huben Professor of Urology and co-author of the original Prostate Cancer Treatment Guideline (1999).
Informational Videos About Prostate Cancer from Roswell Park Cancer Institute
 |
 |
 |
| Proven Therapies | Value of Second Opinion and Treatment Options | Prostate Survivor - Richard |
The Roswell Park Cancer Institute Prostate Cancer Team
| Radiation Oncology: | ||
 |
 |
 |
| Michael Kuettel, MD, PhD, MBA | David Cho, MD | Anurag Singh, MD |
| Medical Oncology: | |||
 |
 |
 |
 |
| Ellis Levine, MD | Donald Trump, MD, FACP | Roberto Pili, MD | Saby George, MD |
| Urology: | ||||
 |
 |
 |
 |
 |
| James Mohler, MD | Khurshid Guru, MD | Robert Huben, MD | Thomas Schwaab, MD, PhD | Willie Underwood III, MD, MPH, MSci |
12
Active Prostate Cancer Clinical Trials at Roswell Park Cancer Institute:
| TRIAL ID | TITLE | TRIAL PHASE |
|---|---|---|
| NCT00887432 | Randomized Placebo-Controlled, Double-Blind Study Of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer | N/A |
| NCT00430183 | Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer | Phase 3 |
| NCT00309985 | CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] | Phase 3 |
| NCT00567580 | A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy | Phase 3 |
| NCT00079001 | A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone | Phase 3 |
| NCT00063882 | A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma | Phase 3 |
| NCT00536991 | A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer | Phase 1/Phase 2 |
| NCT00736645 | A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy | Phase 2 |
| NCT00936390 | A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer | Phase 3 |
| NCT00924469 | A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer | Phase 2 |
| NCT01238172 | The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance | Phase 3 |
| NCT00959959 | ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer | Phase 1/Phase 2 |